August 25, 2014 / 4:03 PM / 3 years ago

BUZZ-Immunovaccine Inc: Ebola vaccine technology succeeds

** Clinical-stage vaccine developer's shares up 25.8 pct at C$1.22 on the Toronto Venture Exchange

** Announces positive results for a vaccine formulated using its DepoVax technology in an Ebola virus challenge study

** All vaccinated cynomolgus monkeys survived the exposure to a lethal dose of the wild type Zaire strain of Ebola virus, believed to be the most lethal, in a preliminary study

** Up to Friday's close, Immunovaccine's stock had more than doubled this year

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below